Wolfe Research analyst Steve Fleishman initiates coverage on SunPower (NASDAQ:SPWR) with a Peer Perform rating.
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002,…